To date, 6 placebo-controlled cardiovascular outcomes trials of GLP-1 agonists in T2DM, and one in patients who are overweight/patients with obesity without diabetes, have demonstrated superiority for 3-point (MACE) reduction (Table 2)
Martha Gulati, director of preventive cardiology at Cedars-Sinai Medical Center
Initially, it was a modest tool in the diabetes arsenal: enhanced insulin release, suppressed glucagon, slowed gastric emptying
Our Atlanta team is here for you every step of the way, providing guidance, answering questions, and making adjustments to your plan to ensure you feel confident and cared for
Success in mating: a coordinated approach to fitness through genotypes incorporating genes for stress resistance and heterozygous advantage under stress